Federal contract for as much as $30M moves Columbus biotech on path to FDA approval

A Columbus biopharmaceutical startup has won up to a $30 million federal contract to develop a treatment for a chemical warfare attack – which also helps in common conditions like pink eye.

Click here to read the complete story.

Story excerpt provided by Columbus Business First.

Written by Carrie Ghose.

Originally published November 2, 2020.